Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 214.73B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.24 |
| Forward PE | 11.19 |
| Dividend | 2.91 (3.36%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 9,516 |
| Average Volume | 4,797 |
| Open | 86.50 |
| Previous Close | 87.00 |
| Day's Range | 86.00 - 87.10 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 60.70 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda
Munich court halts Merck's Keytruda subcutaneous launch in Germany over Halozyme patent dispute. Read more here.
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc . (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline. PLRX stock is showing notable weakness. Check out ...
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administr...
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Dow Movers: MRK, NVDA
In early trading on Thursday, shares of NVIDIA topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.8%. Year to date, NVIDIA registers a 36.2% gain. And t...
Guru Fundamental Report for MRK - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter...
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Dow Movers: MSFT, MRK
In early trading on Wednesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.9%. Year to date, Merck registers a 3.4% gain. And the...
DAX Up Marginally; Merck, Infineon Among Top Gainers
(RTTNews) - The German market's benchmark DAX was up in positive territory at noon on Wednesday, extending previous session's modest upmove. Data showing strong Eurozone private sector growth in Novem...
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Merck & Co Inc at Evercore ISI Healthcare Conference Transcript
Merck & Co Inc at Evercore ISI Healthcare Conference Transcript
Goldman Sachs Raises Merck (MRK) Price Target to $120 | MRK Stock News
Goldman Sachs Raises Merck (MRK) Price Target to $120 | MRK Stock News
17 dividend-stock bargains from a value manager with a stellar track record
John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”
Notable ETF Inflow Detected - XLV, JNJ, ABBV, MRK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
MRK Named A Top Socially Responsible Dividend Stock
Merck & Co Inc (Symbol: MRK) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.3% yie...
Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022
(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLIN...
SCHD: Tops Dividend Competitors On Value, Yield, And Sustainability
SCHD's top holdings, including Merck and Amgen, combine strong profitability, sustainable payout ratios, and attractive valuations. Read why SCHD ETF is a Buy.
Top 10 High-Yield Dividend Stocks For December 2025
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks ...
A Look Into Merck & Co Inc's Price Over Earnings
In the current market session, Merck & Co Inc. (NYSE: MRK) stock price is at $104.80, after a 0.03% drop. However, over the past month, the company's stock spiked by 22.97% , and in the past year, by...